Esketamine for depression: all studies (page 12)

EFFICACY OF KETAMINE AND ESKETAMINE IN TREATMENT-RESISTANT DEPRESSION AMONG OLDER ADULTS (≥65 YEARS): A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED AND REAL-WORLD STUDIES (2023–2025).

Zenodo (CERN European Organization for Nuclear Research) May 1, 2026 Shimul A. Babli*1 Huijuan Song2 Sharmin Ferdous3 Farzana Rahman4 Dilyaver Matakhov5 Hannah Jeyakkodi6 preprint

Late-life treatment-resistant depression (TRD) poses substantial clinical challenges, with limited effectiveness of conventional antidepressants and heightened vulnerability to adverse effects among older adults. Ketamine and esketamine have emerged as rapid-acting antidepressants, but their efficacy and safety in geriatric populations remain incompletely characterised. A systematic review and...

DOI: 10.5281/zenodo.19947544

Is there an independant anti-suicidal effect of esketamine in treatment resistant depression?

Journal of Affective Disorders May 1, 2026 Michel Danon, Gabriela Ostronoff, Anne-Cécile Petit et al.

Regulatory approvals for intranasal esketamine in treatment-resistant depression (TRD) differ with respect to its indication for suicidal ideation. While rapid antidepressant effects are well documented, whether esketamine exerts an anti-suicidal effect independent of mood improvement remains unclear. In this two-center observational study, 261 adults with moderate-to-severe TRD at Sainte-Anne...

DOI: 10.1016/j.jad.2026.121181 Full text Depression Esketamine Suicide

A comprehensive review of the clinical progress of esketamine: From anesthesia to antidepressant therapy.

Medicine May 1, 2026 Hai-Lin Hu, Qi-Zhou Huang, Ping-Xia Xie

Esketamine, the S-enantiomer of ketamine, has emerged as a rapid-acting antidepressant with unique mechanisms. This narrative review synthesizes current evidence on its clinical applications, safety, and regulatory status based on peer-reviewed literature published between January 2000 and March 2024, searched in PubMed, Web of Science, and the Cochrane Library. Esketamine exerts its effects...

DOI: 10.1097/md.0000000000048570 Full text Esketamine Treatment-resistant depression Nmda receptor Anesthesia +2

Higher Neutrophil-to-Lymphocyte Ratio Is Associated With Better Response to Esketamine in Treatment-Resistant Depression: A Post Hoc Exploratory Analysis of Real-World Data.

Journal of Clinical Psychopharmacology May 1, 2026 Matteo Carminati, Mattia Tondello, Chiara Morana et al.

Growing evidence links inflammation with major depressive disorder (MDD) and treatment resistance. The neutrophil-to-lymphocyte ratio (NLR) has emerged as a simple peripheral marker of systemic inflammation and immune balance and it may capture clinically meaningful heterogeneity in inflammatory burden, potentially contributing to variability in antidepressant response and vulnerability to...

DOI: 10.1097/jcp.0000000000002190 Full text Esketamine Treatment-resistant depression Antidepressant response Inflammation +1

Ketamine and Esketamine in Neurology and Psychiatry: An Overview.

Cureus May 1, 2026 Amalesh S Honnekeri

Treatment-resistant depression (TRD) remains a significant clinical concern, particularly in patients who do not achieve adequate response with conventional antidepressant therapies. Ketamine and esketamine, which act on glutamatergic pathways, have been introduced into clinical practice as alternative therapeutic approaches within interventional psychiatry. This narrative review outlines key...

DOI: 10.7759/cureus.108571 Full text Esketamine Major depressive disorder Treatment-resistant depression Interventional psychiatry +1

Pharmacological augmentation in treatment-resistant depression: a neurobiologically informed, practical decision guide for treatment choice with lithium, quetiapine, or esketamine.

International Journal of Psychiatry in Clinical Practice April 29, 2026 David Eckert, Siegfried Kasper

The treatment of treatment-resistant depression (TRD) remains a clinical challenge. Pharmacologically, several augmentation options exist. The aim of this study was to present a mechanistically informed and clinically oriented decision-making framework for the established strategies of lithium, quetiapine, and esketamine. We conducted a narrative, non-systematic review, performing a targeted...

DOI: 10.1080/13651501.2026.2663307 Full text Esketamine Treatment-resistant depression trd Lithium Pharmacological augmentation +1

Repeated intranasal esketamine augmentation in treatment-resistant obsessive-compulsive disorder with comorbid major depressive disorder: a prospective case series.

BMC Psychiatry April 26, 2026 Sergi López-rodríguez, Cinto Segalàs, Eva Real et al.

BACKGROUND: Patients with obsessive–compulsive disorder (OCD) and comorbid major depressive disorder (MDD) represent a severe subgroup with increased treatment resistance, greater functional impairment, and limited therapeutic options. Intranasal esketamine is a rapidly acting treatment for resistant depression, with emerging interest in potential anti-obsessional effects. However, prospective...

DOI: 10.1186/s12888-026-08119-5 Full text Major depressive disorder Comorbidity Intranasal esketamine Obsessive–compulsive disorder +2

Preliminary evidence that serum interleukin-6 is a candidate biomarker of response to esketamine in treatment-resistant depression.

Journal of Psychopharmacology April 24, 2026 Marco Colizzi, Elisa Morandin, Veronica Croccia et al.

Interleukin-6 (IL-6) has been implicated as a potential predictor of ketamine response in treatment-resistant depression (TRD). Esketamine, the S-enantiomer of ketamine, produces rapid antidepressant effects and offers improved safety and intranasal administration. To examine whether baseline IL-6 predicts treatment response to esketamine in individuals with TRD. Fourteen adults with TRD...

DOI: 10.1177/02698811261443676 Full text Esketamine Treatment-resistant depression Biological predictors Glutamatergic system +4

Esketamine-sufentanil PCA reduces postoperative depression state in elderly colorectal cancer patients: a randomized controlled trial.

Scientific Reports April 21, 2026 Rong Ding, Daojie Wang, Guoxin Wang et al.

Elderly colorectal cancer (CRC) patients face high risks of postoperative depression state, inadequately addressed by opioid-based analgesia. Esketamine, an NMDA receptor antagonist with rapid antidepressant effects, offers potential benefits but lacks evidence in this population. This double-blind RCT enrolled 99 elderly (≥ 65 years) CRC resection patients, randomized to three postoperative...

DOI: 10.1038/s41598-026-49287-4 Full text Esketamine Colorectal cancer Elderly Patient-controlled analgesia +1

A systematic review of ketamine and esketamine-induced long-term potentiation and synaptic scaling: Do the molecular and synaptic plasticity effects inform dosing intervals?

Journal of Affective Disorders April 15, 2026 Gia Han Le, Sabrina Wong, Danica E. Johnson et al. 4 citations

Ketamine and esketamine exhibit rapid antidepressant effects in persons with treatment-resistant depression (TRD) and bipolar depression (TRBD). However, the synaptic mechanisms governing dose, frequency, and durability of response remain unclear. This review aims to evaluate the dosing parameters, including minimum dose and optimal dosing intervals, that reliably induce or maintain long-term...

DOI: 10.1016/j.jad.2025.121081 Full text Depressive disorder Ketamine Drug administration schedule Long-term potentiation +2